AC Immune Reports Full-Year 2019 Financial Results and Provides 2020 R&D Outlook
- Ongoing strong financial position with CHF 288.6 million in cash, ensuring the Company is fully financed through Q1 2024, excluding potential incoming milestones
- Received CHF 110 million in upfront and development milestone payments and a USD 50 million equity note in 2019 as a result of the Morphomer™Tau Lilly partnership
- Added new potential CHF 60 million Phase 2 initiation milestone and achieved CHF 10 million milestone in Q1 2020 in Lilly partnership
- Five clinical milestones expected in 2020 including the first Phase 2 readout of an anti-Tau antibody in Alzheimer’s disease(AD)
- Initiated three clinical trials targeting Tau and a substudy within the ongoing Phase 2 Alzheimer’s Prevention Initiative trial
AC Immune SA, a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced financial results for the year ended December 31, 2019, and provided a business and 2020 research and development outlook.